サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529839

CROにおけるIn-vivoオンコロジーの市場規模、シェア、動向分析レポート：適応症別、地域別、セグメント予測、2024年～2030年

Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor, Others), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.20円
CROにおけるIn-vivoオンコロジーの市場規模、シェア、動向分析レポート：適応症別、地域別、セグメント予測、2024年～2030年
出版日: 2024年07月24日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

CROにおけるIn-vivoオンコロジー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、CROにおけるIn-vivoオンコロジーの世界市場規模は2030年までに23億7,000万米ドルに達する見込みです。

同市場は予測期間中にCAGR 8.58％で成長すると予測されています。研究開発活動のアウトソーシングの増加、先端医薬品への高い需要、CROによる国際標準の導入などが市場成長を促進する主な要因です。

さらに、特許切れによる競合の増加、ジェネリック医薬品の急成長、バイオシミラー医薬品のイントロダクションといったプレッシャーが、製薬企業がCROの支援を求める原動力となっています。従って、オンコロジーをベースとする生体内CRO業界は、予測期間中に有利な成長を遂げる可能性があると予測できます。

市場参入企業のリクルートとコミュニケーションのためのモバイル対応イノベーション、ウェブベースのライフサイエンスラボ、ルーチンテストを実行するためのロボットラボなどの技術的進歩は、市場のチャンスとなり得る。世界レベルでは、新規市場への参入を目指すスポンサーや製薬企業にとって、アウトソーシングは解決策のひとつです。ファイザーやグラクソ・スミスクラインなどの大手製薬会社は、現地のCMOやCROと提携し、外資系企業が新興国でマーケティング、規制、製造の目標を達成できるようにすることに成功しています。

さらに、この業界における合併や提携の増加は、今後数年間で市場を拡大すると予想されます。例えば、2023年1月、分析ソリューション企業のブルカーは、前臨床活動の能力を拡大するため、スイスを拠点とする前臨床CROバイオジェネシスを買収しました。

CROにおけるIn-vivoオンコロジー市場レポートハイライト

  • 固形がんセグメントは47.4%の最大シェアを占めました。これは、世界中でがんの罹患率が増加しているためであり、WHOなどの世界機関ががんの罹患率、原因物質、治療法の分析に関心を高めていることが、研究開発を後押ししています。
  • 固形がんをベースとしたモデルでは、患者由来異種移植片が予測期間中に最速のCAGR 9.21%を記録すると予測されています。
  • 2023年の世界シェアは北米が49.97%と最も大きく、米国が大きく貢献しています。これにより研究活動が活発化しています。大手製薬企業やライフサイエンス企業は、同地域でのプレゼンスを確立しており、引き続き市場の成長を牽引しています。
  • アジア太平洋地域は、予測期間中に最も速いCAGRを記録すると予想されます。これは、多くの新興国がアジア太平洋地域に投資していることと、世界プラットフォームに従って臨床試験の評価基準を変更するために規制市場によって様々な改正が行われていることによる。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 CROにおけるIn-vivoオンコロジー市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • CROにおけるIn-vivoオンコロジー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析
    • 主要取引と戦略的提携の分析

第4章 CROにおけるIn-vivoオンコロジー市場：適応症別推定・動向分析

  • CROにおけるIn-vivoオンコロジー市場、適応症別：セグメントダッシュボード
  • CROにおけるIn-vivoオンコロジー市場、適応症別：変動分析
  • 市場推計・予測：適応症別、2018年-2030年

第5章 CROにおけるIn-vivoオンコロジー市場：地域別推定・動向分析

  • 地域別市場シェア分析、2023年および2030年
  • 地域別市場ダッシュボード
  • 世界の地域市場スナップショット
  • 北米
    • 市場推計・予測、2018年-2030年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第6章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレーヤー
    • 企業市場シェア分析、2023年
  • 企業プロファイル
    • Charles River Laboratory（CRL）
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Eurofins Scientific
    • Taconic Biosciences
    • Crown Bioscience
    • Lab Corp
    • WuXi AppTec
    • EVOTEC
    • The Jackson Laboratory
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 5 U.S. Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 Canada Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 7 Mexico Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Europe Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 9 Europe Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 10 UK Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 11 Germany Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 12 France Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Italy Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Spain Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 15 Denmark Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 16 Sweden Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Norway Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 18 Asia Pacific Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 19 Asia Pacific Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 20 Japan Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 21 China Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 22 India Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 23 South Korea Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 24 Australia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Thailand Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 26 Latin America Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 27 Latin America Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 28 Brazil Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Argentina Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 30 Middle East & Africa Oncology Based In-vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 31 Middle East & Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 32 South Africa Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Saudi Arabia Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 34 UAE Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Kuwait Oncology Based In-vivo CRO market, by indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Oncology Based In-vivo CRO Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Oncology Based In-vivo CRO Market snapshot
  • Fig. 11 Oncology Based In-vivo CRO Market driver impact
  • Fig. 12 Oncology Based In-vivo CRO Market restraint impact
  • Fig. 13 Oncology Based In-vivo CRO sector key takeaways (USD Million)
  • Fig. 14 Oncology Based In-vivo CRO Market: Type movement analysis
  • Fig. 15 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 17 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 18 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 19 Solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 20 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 21 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 22 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 25 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 26 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional outlook, 2023 & 2030
  • Fig. 29 North America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 34 UK Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 36 France Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 44 China Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 45 India Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Australia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East & Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait Oncology Based In-vivo CRO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Market participant categorization
目次
Product Code: GVR-1-68038-859-6

Oncology Based In-vivo CRO Market Growth & Trends:

The global oncology based in-vivo CRO market size is expected to reach USD 2.37 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to grow at a CAGR of 8.58% over the forecast period. An increase in outsourcing of R&D activities, high demand for advanced medicines, and implementation of international standards by CROs are key factors driving the market growth.

Furthermore, the pressure from increasing competition due to patent expirations, the rapid growth of generics, and the introduction of biosimilar equivalents are propelling pharmaceutical companies to seek the aid of such organizations. Hence, it can be predicted that the oncology-based in-vivo CRO industry may witness lucrative growth over the forecast period.

Technological advancements such as mobile-enabled innovations for recruiting and communicating with participants, web-based life science labs and robotics labs to perform routine tests can be the opportunities of the market. At a global level, outsourcing is one of the solutions for sponsors and pharma companies seeking to make an entry into a new market. Big pharma companies such as Pfizer and GlaxoSmithKline partner with local CMOs and CROs, which have been successful in enabling foreign companies to achieve marketing, regulatory, and manufacturing goals in emerging economies.

Furthermore, an increase in the number of mergers and collaborations in this industry is expected to expand the market in the coming years. For instance, in January 2023, Bruker, an analytical solutions company, acquired a preclinical Switzerland-based CRO Biogenesis to expand its capabilities in preclinical activities.

Oncology Based In-vivo CRO Market Report Highlights:

  • The solid tumors segment held the largest share of 47.4% owing to the increasing incidence of cancer across the globe, and the growing interest of world agencies such as the WHO in analyzing their prevalence, causative agents, and treatment options is boosting R&D
  • Based on solid tumor-based model, patient-derived xenograft is anticipated to register the fastest CAGR of 9.21% over the forecast period
  • North America accounted for the largest global share of 49.97% in 2023, with the major contributions from the U.S., owing to increased funding available in the region. This has boosted research activities. Major pharmaceutical and life sciences companies continue to drive market growth with their established presence in the region
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period, owing to many developed countries investing in Asia Pacific regions and the various amendments made by the regulatory market to change the clinical trials evaluation standards according to the global platform

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Objectives
    • 1.5.1. Objective-1
    • 1.5.2. Objective-2
    • 1.5.3. Objective-3
  • 1.6. Research Methodology
  • 1.7. Information Procurement
    • 1.7.1. Purchased Database
    • 1.7.2. GVR's Internal Database
    • 1.7.3. Secondary Sources
    • 1.7.4. Primary Research
  • 1.8. Information Or Data Analysis
    • 1.8.1. Data Analysis Models
  • 1.9. Market Formulation & Validation
  • 1.10. Model Details
    • 1.10.1. Commodity Flow Analysis
    • 1.10.2. Parent Market Analysis
  • 1.11. List Of Secondary Sources
  • 1.12. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Oncology Based In-vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Accelerating the time to market
      • 3.2.1.2. Economic efficiency
      • 3.2.1.3. Increasing mergers and collaborations
      • 3.2.1.4. Increasing outsourcing of R&D Activities
    • 3.2.2. Market Restraint Analysis
  • 3.3. Oncology Based In-vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis
    • 3.3.4. Major Deals & Strategic Alliances Analysis

Chapter 4. Oncology Based In-vivo CRO Market: Indication Estimates & Trend Analysis

  • 4.1. Oncology Based In-vivo CRO Market, By Indication: Segment Dashboard
  • 4.2. Oncology Based In-vivo CRO Market, By Indication: Movement Analysis
  • 4.3. Oncology Based In-vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
    • 4.3.1. Blood cancer
      • 4.3.1.1. Blood Cancer Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Syngeneic model
      • 4.3.1.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Patient-derived xenograft
      • 4.3.1.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.1.4. Xenograft
      • 4.3.1.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.2. Solid tumor
      • 4.3.2.1. Solid Tumor Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Syngeneic model
      • 4.3.2.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Patient derived xenograft
      • 4.3.2.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. Xenograft
      • 4.3.2.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Market, 2018 to 2030 (USD Million)
      • 4.3.3.2. Syngeneic model
      • 4.3.3.2.1. Syngeneic model Market, 2018 to 2030 (USD Million)
      • 4.3.3.3. Patient derived xenograft
      • 4.3.3.3.1. Patient derived xenograft Market, 2018 to 2030 (USD Million)
      • 4.3.3.4. Xenograft
      • 4.3.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)

Chapter 5. Oncology Based In-vivo CRO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2023 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Scenario
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Scenario
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
    • 5.4.4. Mexico
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Competitive Scenario
      • 5.4.4.3. Regulatory Scenario
      • 5.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Scenario
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Scenario
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Scenario
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Scenario
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Scenario
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Scenario
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Scenario
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Scenario
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Scenario
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. China
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Scenario
      • 5.6.2.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. India
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Scenario
      • 5.6.3.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Scenario
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Scenario
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Scenario
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Scenario
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Argentina
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Scenario
      • 5.7.2.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Scenario
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Scenario
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Scenario
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Scenario
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2023
  • 6.2. Company Profiles
    • 6.2.1. Charles River Laboratory (CRL)
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. ICON Plc
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Thermo Fisher Scientific Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Eurofins Scientific
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Taconic Biosciences
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Crown Bioscience
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Lab Corp
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. WuXi AppTec
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. EVOTEC
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. The Jackson Laboratory
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives